CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn’s lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.
CytoDyn CEO Highlights PRO 140 for Investors
Interview focused on company milestones, a pending acquisition and an array of new indications beyond the expected FDA approval for HIV treatmentView Video
View Press Releases